CD33 Targeting Services

Inquiry

CD ComputaBio now offers professional CD33 targeting services using computational approaches to meet your research needs.

Research progress

CD33 is a transmembrane receptor expressed on myeloid cells. It is generally considered myeloid specific, but can also be found on some lymphocytes. It binds sialic acid and is therefore a member of the SIGLEC family of lectins. The extracellular portion of this receptor contains two immunoglobulin domains (one IgV and one IgC2 domain), placing CD33 in the immunoglobulin superfamily. The intracellular portion of CD33 contains an immunoreceptor tyrosine inhibitory motif (ITIM) that is involved in inhibiting cellular activity. CD33 has been found to be abnormally expressed in some cases of plasma cell myeloma. It is an excellent bone marrow marker and is often used in the diagnosis of adult acute myeloid leukemia.

CD33: The most promising target of AML

CD33 is a 67KD glycosylated transmembrane protein belonging to the Siglec family. Activated after cross-linking or ligand binding, mediates inhibitory signals, and regulates intracellular calcium mobilization, cell adhesion, leukemia cell apoptosis, myeloid cell maturation, and cytokine production. CD33 is considered to be the most potential AML (acute myeloid leukemia) target. CD33 also controls the activation of microglia, but in Alzheimer's disease, it is overdriven in the presence of amyloid and tau proteins, whose expression is known to correlate with TREM2. CD33 is one of the top AD risk factors identified by GWAS. Therefore, CD33 can serve as both a target for AD drug development and an important target for myeloma disease, and is a potential candidate for the development of AD and myeloma disease treatment drugs.

CD33 in Alzheimer's  disease Figure 1. CD33 in Alzheimer's disease.

During differentiation, CD33 is decreased on mature granulocytes but is retained on macrophages, monocytes and dendritic cells. CD33 has limited expression in non-hematopoietic tissues but is highly expressed in AML cells. In addition, CD33 has now been demonstrated to be expressed in leukemic progenitor cells, making this molecule a very promising therapeutic target for AML.

Siglec family. Figure 2. Siglec family. (Huan Cao and Paul R. Crocker. 2011)

Our Services

  • CD33 inhibitor design
  • Based on similarity to natural ligands, we provide professional CD33 inhibitor design services. In addition to small molecule inhibitors, we also provide design and optimization services for peptide and protein inhibitors. Our inhibitor design approach includes:

    • Structure-Based Inhibitor Design
    • Fragment-based inhibitor design
  • Biological Data Analysis
  • CD ComputaBio now offers comprehensive data analysis services to discover new knowledge from all types of biological data. We have created an efficient data analysis pipeline with a combination of mathematics and programming to perform the required analysis for a client's specific technical or biological research problem.

  • Antibody Drug Discovery Service
  • CD ComputaBio has extensive knowledge and experience in antibody drug discovery services. We collaborate with many scientists from many biotech companies and research institutions. We have extensive experience in this area and can meet your research needs. Our antibody drug discovery services include:

    • Antibody Structure Prediction
    • Antibody Reformatting Service
    • Antibody Modeling Services
    • Antibody Characterization and Analysis
    • Antibody Docking Service
    • Antibody Molecular Dynamics Service
    • Antibodv De Novo Design

Our Capabilities

CD ComputaBio provides professional antibody drug discovery service to meet the specific needs of regular customers on time and according to budget. CD ComputaBio relies on world-class technical expertise, we provide customers with the best quality one-stop antibody drug discovery service, including the development of solutions according to different scientific research needs.

Traditional workflow of  structure-based drug design (SBDD) and ligand-based drug design (LBDD). Figure 3. Traditional workflow of structure-based drug design (SBDD) and ligand-based drug design (LBDD).

Our Univariate Analysis Service Targeting CD33

CD ComputaBio can describe some methods in univariate data, including central tendency (mean, mode, and median) and dispersion: range, variance, maximum, minimum, quartiles and standard deviation. Univariate analysis is probably the simplest form of statistical analysis. Univariate analysis is common in statistical analysis and involves only one variable. Analysis results are descriptive or inferential, so this analysis is widely used to analyze data collected from proteomics or metabolomics. We can provide you with but not limited to the following services:

  • Correlation Analysis Service
  • Fold Change Analysis
  • T-test Service
  • ANOVA Service
  • SAM Service
  • Volcano Plot Service

References

  1. Jiang T, Yu J T, Hu N, et al. CD33 in Alzheimer's Disease. Molecular Neurobiology, 2014, 49(1):529-35.
  2. Huan Cao and Paul R. Crocker,Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology, 2011, 132, 18–26
* For Research Use Only.
Related Services
logo
Give us a free call

Send us an email

Copyright © CD ComputaBio. All Rights Reserved.
  • twitter
Top